Sleep Apnea in Heart Failure With Preserved Ejection Fraction

Mayo Clinic48 enrolled

Overview

This is a prospective interventional study to better understand i) the prevalence of Obstructive Sleep Apnea (OSA) in Heart Failure with preserved Ejection Fraction (HFpEF), ii) its hemodynamic correlates, and iii) the impact of intervention with Continuous Positive Airway Pressure (CPAP) on quality of life.

This is a prospective non-randomized observational study which will recruit patients with gold standard HFpEF defined by exercise catheterization or following HF hospitalization. The prevalence of OSA will be determined in all HFpEF patients at baseline using home sleep apnea testing and all patients will complete the Mayo Sleep Questionnaire. Patients with known OSA at baseline will also be included only for the baseline assessment to accurately estimate prevalence of OSA in gold standard diagnosed HFpEF. The subset of initially recruited patients with HFpEF who have newly diagnosed OSA will be offered and initiated on CPAP therapy to treat their underlying OSA. Repeat evaluation after 3 months of CPAP therapy for end point assessment with remote accelerometry (2 weeks prior to study completion), ESS and KCCQ, which will all be identical to baseline measurements.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Heart Failure Obstructive Sleep Apnea

Interventions

Home sleep apnea testingDIAGNOSTIC_TEST

Participants will be monitored with a WatchPAT device for home based diagnosis of OSA (for patients hospitalized with HFpEF, the sleep test may be performed in the hospital or at home).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of HFpEF by catheterization with resting PCWP\>15 mmHg or exercise PCWP\>25 mmHg or hospitalization with HFpEF * Ambulatory (not wheelchair/scooter dependent) * If no known diagnosis of OSA, must not be pacemaker dependent with either atrial pacing or VVI without sinus rhythm * If no known diagnosis of OSA, must be able to temporarily hold nitrates or alpha channel blockers for home WatchPAT testing (3 hour washout period) Exclusion Criteria: * Ejection fraction \<40% * Obstructive hypertrophic cardiomyopathy * Constrictive pericarditis or tamponade * Active myocarditis * Complex congenital heart disease * Other valve disease requiring surgical intervention * Terminal illness (other than HF) with expected survival of less than 1 year * Inability to comply with planned study procedures * Pregnancy or breastfeeding mothers

Locations (1)

Mayo Clinic Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Determine the impact of intervention with CPAP therapy on quality of life as assessed by Kansas City Cardiomyopathy Questionnaire scores (Scale 0-100) in patients with Obstructive Sleep Apnea at Baseline

Quality of life will be assessed by Kansas City Cardiomyopathy Questionnaire (Scale 0-100)

Time frame: 6 months

Secondary Outcomes

Determine the impact of intervention with CPAP therapy on average daily accelerometry units (scale -1000 to 10000 units) by wearable accelerometers in patients with Obstructive Sleep Apnea at Baseline

Average daily accelerometry units by wearable accelerometers (scale -1000 to 10000 units)

Time frame: 6 months

Determine the impact of intervention with CPAP therapy on hours active per day (number of hours of activity per day range 0-12 hours) by wearable accelerometers in patients with Obstructive Sleep Apnea at Baseline

Hours of activity per day by wearable accelerometers (number of hours of activity per day range 0-12 hours)

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.